Lorillard Management Discusses Q2 2012 Results - Earnings Call Transcript

Lorillard (LO)

Q2 2012 Earnings Call

July 25, 2012 9:00 am ET


Robert Bannon - Director of Investor Relations

Murray S. Kessler - Chairman, Chief Executive Officer and President

David H. Taylor - Chief Financial Officer and Executive Vice President of Finance & Planning


Vivien Azer - Citigroup Inc, Research Division

Nik Modi - UBS Investment Bank, Research Division

Thilo Wrede - Jefferies & Company, Inc., Research Division

David J. Adelman - Morgan Stanley, Research Division

Judy E. Hong - Goldman Sachs Group Inc., Research Division

Andrew Kieley - Deutsche Bank AG, Research Division

Christopher Growe - Stifel, Nicolaus & Co., Inc., Research Division

Ann H. Gurkin - Davenport & Company, LLC, Research Division

Christopher Ferrara - BofA Merrill Lynch, Research Division

Bonnie Herzog - Wells Fargo Securities, LLC, Research Division

Priya Ohri-Gupta - Barclays Capital, Research Division



Good day, ladies and gentlemen, and welcome to the Lorillard, Inc. Second Quarter 2012 Earnings Conference Call. My name is Paula, and I'll be your operator for today's call. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. At this time, I would like to turn the conference over to your host for today's call, Mr. Bob Bannon. You may begin, sir.

Robert Bannon

Thank you, Paula, and good morning, everyone. I'm Bob Bannon, Lorillard's Director of Investor Relations, and joining me on today's call are Murray Kessler, Lorillard's Chairman, President and Chief Executive Officer; and David Taylor, its Chief Financial Officer.

By now, you should have received a copy of our second quarter 2012 earnings release. It can be found on the company's website, lorillard.com, under News Releases.

Before we begin, I'd like to remind you that some of the comments on today's call, and some of the responses to your questions, may contain forward-looking statements. These statements are subject to the risks and uncertainties as described in the company's earnings release and in other filings with the SEC.

Also, certain financial information such as adjusted net income and adjusted earnings per share that will be discussed on today's conference call, is presented on a non-GAAP basis. The description most directly comparable GAAP measure and reconciliation between the non-GAAP and GAAP measures are provided in the company's earnings release, which is available on our website. I'd now like to turn the call over to Murray Kessler.

Murray S. Kessler

Thank you, Bob. In a quarter that saw heightened competitive activity and was measured against extremely difficult comps, I'm pleased that Lorillard's underlying results were solid and outperformed the industry as a whole. The company increased net sales 2.3%, gained market share, protected gross margins and grew adjusted EPS by 6.8%. These gains compare to the second quarter of last year when our unit volume was up 9.9%, net sales were up 11.3% and EPS was up 18.5%.

Let me give you some detail on the quarter, why I expect the company to perform well in the second half and why we are reaffirming our 2012 goal of a double-digit total shareholder return as measured by EPS growth and the dividend yield. I'll also give you brief updates on the FDA's review of menthol and our acquisition of blu ecigs.

Let's start with second quarter volume. First, total Lorillard wholesale unit volume decreased 1.2% versus a year ago with Newport Menthol down 0.9%. While still outperforming the industry, this trend is modestly below our typical trend on the core business and primarily traces to the impact of the tax status change on Native American reservations in New York.

For the last 3 quarters, the volume impact in New York was more than upset by the launch of Newport Non-Menthol, our geographic rollout of Newport Menthol promotions, and robust Maverick growth that drove a remarkable increase in volume. So the impact to the business was previously strictly limited to a negative drag on net pricing, as consumer shifted their purchases to outlets that carried buydown promotion.

Those strategic initiatives that previously more than offset New York's losses continue to perform well, but in this quarter did not fully offset the loss. The good news is, as we enter the third quarter, we have now fully lapped the New York changes so this drag on volume and pricing is behind us. And while we look forward to the next stage of our strategic plan, and once again delivering strong volume growth, I'll remind you that the vast majority of our profitability comes from Newport Menthol. So it's always good news when we see our flagship brand continue to outperform in the category, while preserving its strong brand equity despite multiple launches and promotions into the menthol segment by competitors.

In regards to the next steps on our cigarette adjacency strategy, we had planned and are fully ready to launch additional new products this year that were intended to keep last year's level of accelerated growth going. Unfortunately, substantially equivalent products like these now require FDA approval prior to launch.

The FDA has not approved one single substantial equivalent application since premarket approval was required starting March 2011. Even though the statutes suggest this preapproval process should only take 90 days. As a result, our strategic expansion plans have been temporarily slowed down, but all indications from the FDA is that they are in process.

On a 6-month basis, shipment comparisons are still being affected by inventory. As our price increase was mid-June this year versus July 1 last year, our first half comparison is still being negatively affected by the 400 million units we spoke about during the first quarter conference call. That is, wholesalers built inventory during this year's second quarter and then mostly reduced it during the final 2 weeks of the quarter following the implementation of our price increases. This reduction in inventory took place in the third quarter last year. So for Lorillard, while there was no meaningful inventory effect in Q2, there still is in the 6-month comparison.

Read the rest of this transcript for free on seekingalpha.com

If you liked this article you might like

Reynolds Drops on Lorillard Debt; Stocks End Mixed on Jobs Report

Reynolds Drops on Lorillard Debt; Stocks End Mixed on Jobs Report

Lorillard (LO) Stock Continues To Gain Following FTC Approval of Merger with Reynolds American

Lorillard (LO) Stock Continues To Gain Following FTC Approval of Merger with Reynolds American

Stocks Extend Gains, Undeterred by Higher Dollar and Lower Oil

Stocks Extend Gains, Undeterred by Higher Dollar and Lower Oil

FTC Clears Reynolds to Inhale Lorillard for $27B by End of June

FTC Clears Reynolds to Inhale Lorillard for $27B by End of June

Lorrilard (LO) Stock Rising on Approval of Reynolds Merger

Lorrilard (LO) Stock Rising on Approval of Reynolds Merger